Dice Therapeutics Inc   (DICE)
Other Ticker:  
Price: $47.5500 $0.03 0.063%
Day's High: $47.8301 Week Perf: 0.36 %
Day's Low: $ 47.46 30 Day Perf: 1.34 %
Volume (M): 4,333 52 Wk High: $ 47.90
Volume (M$): $ 206,029 52 Wk Avg: $36.13
Open: $47.59 52 Wk Low: $25.51

 Market Capitalization (Millions $) 2,250
 Shares Outstanding (Millions) 47
 Employees 10
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -104
 Cash Flow (TTM) (Millions $) 57
 Capital Exp. (TTM) (Millions $) 3

Dice Therapeutics Inc
Dice Therapeutics Inc. is a biotechnology company that focuses on developing new medicines for patients with rare endocrine and metabolic disorders. The company is headquartered in San Francisco, California, and it was founded in 2020 by a team of experienced biotechnology executives.

The main focus of Dice Therapeutics Inc. is to develop next-generation gene therapies and hormone replacement therapies to treat endocrine and metabolic disorders. These therapies aim to provide patients with long-term benefits by correcting genetic defects that cause these disorders.

The company's research and development efforts are focused on three key areas:

Gene Therapy: Dice Therapeutics Inc. is developing gene therapies to address rare genetic diseases that affect hormone production and regulation. The company uses its proprietary technology to deliver genes that can correct or replace malfunctioning genes in patients.

Hormone Replacement Therapy: The company is developing hormone replacement therapies for patients with rare endocrine disorders, including those that affect the pituitary, adrenal, and thyroid glands. The company's hormone therapy aims to provide long-term, stable hormone replacement that can improve quality of life for patients.

Drug Discovery: Dice Therapeutics Inc. is conducting research on new compounds that can be used to treat rare endocrine and metabolic disorders. The company uses state-of-the-art screening technologies to identify potential drug candidates.

The company's management team includes experienced biotechnology executives who have a proven track record of developing successful therapies for rare diseases. The team includes Dr. Douglas E. Williams as CEO, Dr. Alan J. Lewis as Chairman of the Board, and Dr. Vikas Goyal as Chief Medical Officer.

In conclusion, Dice Therapeutics Inc. is a biotechnology company with a clear mission to develop new therapies for patients with rare endocrine and metabolic disorders. The company's focus on gene therapy, hormone replacement therapy, and drug discovery makes it well-positioned to address these challenging diseases. With an experienced management team and a commitment to innovation, Dice Therapeutics Inc. is a promising company in the biotechnology space.

   Company Address: 400 East Jamie Court South San Francisco 94080 CA
   Company Phone Number: 566-1420   Stock Exchange / Ticker: NASDAQ DICE
   DICE is expected to report next financial results on March 14, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Dice Therapeutics Inc

DICE Therapeutics Inc. Releases Second Quarter 2023 Financials Reflecting Initial Operating Loss of $39.497 Million

Exciting Future Awaits the Stock Market as Dice Therapeutics Inc. Eyes Financial Turnaround
The stock market has always been a place of immense optimism and opportunity, where investors eagerly await news and numbers that could potentially shape their financial future. In the ever-evolving world of the stock market, there is always something new to capture our attention.
Today, the spotlight falls on Dice Therapeutics Inc., a major player in the pharmaceutical preparations industry. Industry consultants have started analyzing the second quarter of 2023 numbers, and initial figures seem to reflect a notable operating loss of $-39.497 million. While this may raise some concerns, it's important to put these results into perspective.

Dice Therapeutics Inc

DICE Therapeutics Inc Shines Amidst Corporate Performance Reports for Q1 2023, Promising Shareholders a Bright Future

Dice Therapeutics Inc: A Promising Future for Shareholders
The stockholders of Dice Therapeutics Inc have been anxiously waiting for some good news, and it seems to be on the horizon. As the company approaches the end of its earnings cycle for fiscal January to March 31, 2023, shareholders are hopeful and expectant of additional revenue streams to come in soon. While the organization has suffered losses during the emerging cycle, the CFO is pursuing new business models, and shareholders are confident that these efforts will bear fruit.
Investors have paid close attention to the Major Pharmaceutical Preparations company's operating deficit, which was at $-31.575 million during the matching time. Nevertheless, they are optimistic that things will turn around soon. Although the net loss increased from $-18.591 million to $-25.646 million during the emerging cycle, investors believe that the worst is behind them, and the company is poised for growth.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com